Top

Current Osteoporosis Reports

Published in:

01-08-2017 | Osteocytes (T Bellido and J Klein-Nulend, Section Editors)

Connexins and Pannexins in Bone and Skeletal Muscle

Authors: Lilian I. Plotkin, Hannah M. Davis, Bruno A. Cisterna, Juan C. Sáez

Published in: Current Osteoporosis Reports | Issue 4/2017

Abstract

Purpose of review

To discuss current knowledge on the role of connexins and pannexins in the musculoskeletal system.

Recent findings

Connexins and pannexins are crucial for the development and maintenance of both bone and skeletal muscle. In bone, the presence of connexin and more recently of pannexin channels in osteoblasts, osteoclasts, and osteocytes has been described and shown to be essential for normal skeletal development and bone adaptation. In skeletal muscles, connexins and pannexins play important roles during development and regeneration through coordinated regulation of metabolic functions via cell-to-cell communication. Further, under pathological conditions, altered expression of these proteins can promote muscle atrophy and degeneration by stimulating inflammasome activity.

Summary

In this review, we highlight the important roles of connexins and pannexins in the development, maintenance, and regeneration of musculoskeletal tissues, with emphasis on the mechanisms by which these molecules mediate chemical (e.g., ATP and prostaglandin E2) and physical (e.g., mechanical stimulation) stimuli that target the musculoskeletal system and their involvement in the pathophysiological changes in both genetic and acquired diseases.

Plotkin LI, Stains JP. Connexins and pannexins in the skeleton: gap junctions, hemichannels and more. Cell Mol Life Sci. 2015;72:2853–67. doi:10.1007/s00018-015-1963-6.CrossRefPubMedPubMedCentral

Goodenough DA, Paul DL. Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol. 2003;4:285–94. doi:10.1038/nrm1072.CrossRefPubMed

Plotkin LI, Laird DW, Amedee J. Role of connexins and pannexins during ontogeny, regeneration, and pathologies of bone. BMC Cell Biol. 2016;17:29–38. doi:10.1186/s12860-016-0088-6.CrossRef

Penuela S, Harland L, Simek J, et al. Pannexin channels and their links to human disease. Biochem J. 2014;461:371–81. doi:10.1042/BJ20140447.CrossRefPubMed

Sosinsky GE, Boassa D, Dermietzel R, et al. Pannexin channels are not gap junction hemichannels. Channels (Austin). 2011;5:193–7. doi:10.4161/chan.5.3.15765.CrossRef

Sáez JC, Cisterna BA, Vargas A, et al. Regulation of pannexin and connexin channels and their functional role in skeletal muscles. Cell Mol Life Sci. 2015;72:2929–35. doi:10.1007/s00018-015-1968-1.CrossRefPubMed

Delgado-Calle J, Bellido T. Osteocytes and skeletal pathophysiology. Curr Mol Biol Rep. 2015;1:157–67. doi:10.1007/s40610-015-0026-y.CrossRefPubMedPubMedCentral

Weinger JM, Holtrop ME. An ultrastructural study of bone cells: the occurrence of microtubules, microfilaments and tight junctions. Calcif Tissue Res. 1974;14:15–29.CrossRefPubMed

Civitelli R, Beyer EC, Warlow PM, et al. Connexin43 mediates direct intercellular communication in human osteoblastic cell networks. J Clin Invest. 1993;91:1888–96. doi:10.1172/JCI116406.CrossRefPubMedPubMedCentral

10.

Ilvesaro J, Väänänen K, Tuukkanen J. Bone-resorbing osteoclasts contain gap-junctional connexin-43. J Bone Min Res. 2000;15:919–26. doi:10.1359/jbmr.2000.15.5.919.CrossRef

11.

Yellowley CE, Li Z, Zhou Z, et al. Functional gap junctions between osteocytic and osteoblastic cells. J Bone Miner Res. 2000;15:209–17. doi:10.1359/jbmr.2000.15.2.209.CrossRefPubMed

12.

Lecanda F, Towler DA, Ziambaras K, et al. Gap junctional communication modulates gene expression in osteoblastic cells. Mol Biol Cell. 1998;9:2249–58. doi:10.1091/mbc.9.8.2249.CrossRefPubMedPubMedCentral

13.

Lecanda F, Warlow PM, Sheikh S, et al. Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J Cell Biol. 2000;151:931–44. doi:10.1083/jcb.151.4.931.CrossRefPubMedPubMedCentral

14.

Thi MM, Urban-Maldonado M, Spray DC, et al. Characterization of human telomerase reverse transcriptase (hTERT) immortalized osteoblast cell lines generated from wildtype and connexin43-null mouse calvaria. Am J Physiol Cell Physiol. 2010;299:C994–C1006. doi:10.1152/ajpcell.00544.2009.CrossRefPubMedPubMedCentral

15.

Reaume AG, de Sousa PA, Kulkarni S, et al. Cardiac malformation in neonatal mice lacking connexin43. Science. 1995;267:1831–4. doi:10.1126/science.7892609.CrossRefPubMed

16.

Gonzalez-Nieto D, Li L, Kohler A, et al. Connexin-43 in the osteogenic BM niche regulates its cellular composition and the bidirectional traffic of hematopoietic stem cells and progenitors. Blood. 2012;119:5144–54. doi:10.1182/blood-2011-07-368506.CrossRefPubMedPubMedCentral

17.

Watkins M, Grimston SK, Norris JY, et al. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. Mol Biol Cell. 2011;22:1240–51. doi:10.1091/mbc.E10-07-0571.CrossRefPubMedPubMedCentral

18.

Chung D, Castro CH, Watkins M, et al. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J Cell Sci. 2006;119:4187–98. doi:10.1242/jcs.03162.CrossRefPubMed

19.

Plotkin LI, Lezcano V, Thostenson J, et al. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 2008;23:1712–21. doi:10.1359/jbmr.080617.CrossRefPubMedPubMedCentral

20.

Zhang Y, Paul EM, Sathyendra V, et al. Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone. PLoS ONE. 2011;6:e23516. doi:10.1371/journal.pone.0023516.CrossRefPubMedPubMedCentral

21.

Bivi N, Condon KW, Allen MR, et al. Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation. J Bone Miner Res. 2012;27:374–89. doi:10.1002/jbmr.548.CrossRefPubMed

22.

• Shen H, Grimston S, Civitelli R, et al. Deletion of connexin43 in osteoblasts/osteocytes leads to impaired muscle formation in mice. J Bone Miner Res. 2014;30:596–605. doi:10.1002/jbmr.2389. First demonstration of the role of osteoblastic Cx43 on skeletal muscle formation. CrossRef

23.

Kruger O, Plum A, Kim JS, et al. Defective vascular development in connexin 45-deficient mice. Development. 2000;127:4179–93.PubMed

24.

Chaible LM, Sanches DS, Cogliati B, et al. Delayed osteoblastic differentiation and bone development in Cx43 knockout mice. Toxicol Pathol. 2011;39:1046–55. doi:10.1177/0192623311422075.CrossRefPubMed

25.

Stains JP, Civitelli R. Gap junctions in skeletal development and function. Biochim Biophys Acta. 2005;1719:69–81. doi:10.1016/j.bbamem.2005.10.012.CrossRefPubMed

26.

Paic F, Igwe JC, Nori R, et al. Identification of differentially expressed genes between osteoblasts and osteocytes. Bone. 2009;45:682–92. doi:10.1016/j.bone.2009.06.010.CrossRefPubMedPubMedCentral

27.

Pacheco-Costa R, Hassan I, Reginato RD, et al. High bone mass in mice lacking Cx37 due to defective osteoclast differentiation. J Biol Chem. 2014;289:8508–20. doi:10.1074/jbc.M113.529735.CrossRefPubMedPubMedCentral

28.

Pacheco-Costa R, Kadakia JR, Atkinson EG, et al. Connexin37 deficiency alters organic bone matrix, cortical bone geometry, and increases Wnt/beta-catenin signaling. Bone. 2017;97:105–13. doi:10.1016/j.bone.2017.01.010.CrossRefPubMed

29.

Loiselle AE, Paul EM, Lewis GS, et al. Osteoblast and osteocyte-specific loss of Connexin43 results in delayed bone formation and healing during murine fracture healing. J Orthop Res. 2013;31:147–54. doi:10.1002/jor.22178.CrossRefPubMed

30.

Maass K, Ghanem A, Kim JS, et al. Defective epidermal barrier in neonatal mice lacking the C-terminal region of connexin43. Mol Biol Cell. 2004;15:4597–608. doi:10.1091/mbc.E04-04-0324.CrossRefPubMedPubMedCentral

31.

Pacheco-Costa R, Davis HM, Sorenson C, et al. Defective cancellous bone structure and abnormal response to PTH in cortical bone of mice lacking Cx43 cytoplasmic C-terminus domain. Bone. 2015;81:632–43. doi:10.1016/j.bone.2015.09.011.CrossRefPubMedPubMedCentral

32.

Moorer MC, Hebert C, Tomlinson RE, et al. Defective signaling, osteoblastogenesis, and bone remodeling in a mouse model of connexin43 C-terminal truncation. J Cell Sci. 2017;130:531–40. doi:10.1242/jcs.197285.CrossRefPubMedPubMedCentral

33.

Bond SR, Lau A, Penuela S, et al. Pannexin 3 is a novel target for Runx2, expressed by osteoblasts and mature growth plate chondrocytes. J Bone Miner Res. 2011;26:2911–22. doi:10.1002/jbmr.509.CrossRefPubMed

34.

Xiao Z, Camalier CE, Nagashima K, et al. Analysis of the extracellular matrix vesicle proteome in mineralizing osteoblasts. J Cell Physiol. 2007;210:325–35. doi:10.1002/jcp.20826.CrossRefPubMed

35.

Cheung WY, Fritton JC, Morgan SA, et al. Pannexin-1 and P2X7-receptor are required for apoptotic osteocytes in fatigued bone to trigger RANKL production in neighboring bystander osteocytes. J Bone Miner Res. 2016;31:890–9. doi:10.1002/jbmr.2740.CrossRefPubMed

36.

Caskenette D, Penuela S, Lee V, et al. Global deletion of Panx3 produces multiple phenotypic effects in mouse humeri and femora. J. Anat. 2016; 28(5):746–56. doi:10.1111/joa.12437.CrossRefPubMedPubMedCentral

37.

Genetos DC, Zhou Z, Li Z, et al. Age-related changes in gap junctional intercellular communication in osteoblastic cells. J Orthop Res. 2012;30:1979–84. doi:10.1002/jor.22172.CrossRefPubMedPubMedCentral

38.

•• Davis HM, Pacheco-Costa R, Atkinson EG, et al. Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging. Aging Cell. 2017; doi:10.1111/acel.12586. This study describes for the first time the molecular signaling pathways that lead to osteocyte apoptosis and osteoclast recruitment in the absence of Cx43 and with aging. CrossRefPubMedPubMedCentral

39.

Kar R, Riquelme MA, Werner S, et al. Connexin 43 channels protect osteocytes against oxidative stress-induced cell death. J Bone Miner Res. 2013;28:1611–21. doi:10.1002/jbmr.1917.CrossRefPubMed

40.

Almeida M, Han L, Martin-Millan M, et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007;282:27285–97. doi:10.1074/jbc.M702810200.CrossRefPubMed

41.

Paznekas WA, Boyadjiev SA, Shapiro RE, et al. Connexin 43 (GJA1) mutations cause the pleiotropic phenotype of oculodentodigital dysplasia. Am J Hum Genet. 2003;72:408–18. doi:10.1086/346090.CrossRefPubMed

42.

Alao MJ, Bonneau D, Holder-Espinasse M, et al. Oculo-dento-digital dysplasia: lack of genotype-phenotype correlation for GJA1 mutations and usefulness of neuro-imaging. Eur J Med Genet. 2010;53:19–22. doi:10.1016/j.ejmg.2009.08.007.CrossRefPubMed

43.

Brice G, Ostergaard P, Jeffery S, et al. A novel mutation in GJA1 causing oculodentodigital syndrome and primary lymphoedema in a three generation family. Clin Genet. 2013;84:378–81. doi:10.1111/cge.12158.CrossRefPubMed

44.

Himi M, Fujimaki T, Yokoyama T, et al. A case of oculodentodigital dysplasia syndrome with novel GJA1 gene mutation. Jpn J Ophthalmol. 2009;53:541–5. doi:10.1007/s10384-009-0711-6.CrossRefPubMed

45.

Gabriel LA, Sachdeva R, Marcotty A, et al. Oculodentodigital dysplasia: new ocular findings and a novel connexin 43 mutation. Arch Ophthalmol. 2011;129:781–4. doi:10.1001/archophthalmol.2011.113.CrossRefPubMed

46.

Furuta N, Ikeda M, Hirayanagi K, et al. A novel GJA1 mutation in oculodentodigital dysplasia with progressive spastic paraplegia and sensory deficits. Intern Med. 2012;51:93–8. doi:10.2169/internalmedicine.51.5770.CrossRefPubMed

47.

Fenwick A, Richardson RJ, Butterworth J, et al. Novel mutations in GJA1 cause oculodentodigital syndrome. J Dent Res. 2008;87:1021–6. doi:10.1177/154405910808701108.CrossRefPubMed

48.

Debeer P, Van EH, Huysmans C, et al. Novel GJA1 mutations in patients with oculo-dento-digital dysplasia (ODDD). Eur J Med Genet 2005;48:377–87. doi:10.1016/j.ejmg.2005.05.003.CrossRefPubMed

49.

de la Parra DR, Zenteno JC. A new GJA1 (connexin 43) mutation causing oculodentodigital dysplasia associated to uncommon features. Ophthalmic Genet. 2007;28:198–202. doi:10.1080/13816810701538620.CrossRefPubMed

50.

Kjaer KW, Hansen L, Eiberg H, et al. Novel connexin 43 (GJA1) mutation causes oculo-dento-digital dysplasia with curly hair. Am. J. Med. Genet. A. 2004;127:152–57. doi:10.1002/ajmg.a.20614.CrossRefPubMed

51.

Itro A, Marra A, Urciuolo V, et al. Oculodentodigital dysplasia. A case report. Minerva Stomatol. 2005;54:453–9.PubMed

52.

Izumi K, Lippa AM, Wilkens A, et al. Congenital heart defects in oculodentodigital dysplasia: Report of two cases. Am J Med Genet A. 2013;161:3150–4. doi:10.1002/ajmg.a.36159.CrossRef

53.

Jamsheer A, Sowinska-Seidler A, Socha M, et al. Three novel GJA1 missense substitutions resulting in oculo-dento-digital dysplasia (ODDD)—further extension of the mutational spectrum. Gene. 2014;539:157–61. doi:10.1016/j.gene.2014.01.066.CrossRefPubMed

54.

Jamsheer A, Wisniewska M, Szpak A, et al. A novel GJA1 missense mutation in a Polish child with oculodentodigital dysplasia. J Appl Genet. 2009;50:297–9. doi:10.1007/BF03195687.CrossRefPubMed

55.

Joss SK, Ghazawy S, Tomkins S, et al. Variable expression of neurological phenotype in autosomal recessive oculodentodigital dysplasia of two sibs and review of the literature. Eur J Pediatr. 2008;167:341–5. doi:10.1007/s00431-007-0468-1.CrossRefPubMed

56.

Kellermayer R, Keller M, Ratajczak P, et al. Bigenic connexin mutations in a patient with hidrotic ectodermal dysplasia. Eur J Dermatol. 2005;15:75–9.PubMed

57.

Kelly SC, Ratajczak P, Keller M, et al. A novel GJA 1 mutation in oculo-dento-digital dysplasia with curly hair and hyperkeratosis. Eur J Dermatol. 2006;16:241–5.PubMed

58.

Laird DW. Syndromic and non-syndromic disease-linked Cx43 mutations. FEBS Lett. 2014;588:1339–48. doi:10.1016/j.febslet.2013.12.022.CrossRefPubMed

59.

Paznekas WA, Karczeski B, Vermeer S, et al. GJA1 mutations, variants, and connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype. Hum Mutat. 2009;30:724–33. doi:10.1002/humu.20958.CrossRefPubMed

60.

Honkaniemi J, Kalkkila JP, Koivisto P, et al. Letter to the editor: Novel GJA1 mutation in oculodentodigital dysplasia. Am J Med Genet A. 2005;139:48–9. doi:10.1002/ajmg.a.30925.CrossRefPubMed

61.

Pizzuti A, Flex E, Mingarelli R, et al. A homozygous GJA1 gene mutation causes a Hallermann-Streiff/ODDD spectrum phenotype. Hum Mutat. 2004;23:286. doi:10.1002/humu.9220.CrossRefPubMed

62.

Richardson R, Donnai D, Meire F, et al. Expression of Gja1 correlates with the phenotype observed in oculodentodigital syndrome/type III syndactyly. J Med Genet. 2004;41:60–7. doi:10.1136/jmg.2003.012005.CrossRefPubMedPubMedCentral

63.

van Steensel MA, Spruijt L, van der Burgt I, et al. A 2-bp deletion in the GJA1 gene is associated with oculo-dento-digital dysplasia with palmoplantar keratoderma. Am J Med Genet A. 2005;132A:171–4. doi:10.1002/ajmg.a.30412.CrossRefPubMed

64.

Vasconcellos JP, Melo MB, Schimiti RB, et al. A novel mutation in the GJA1 gene in a family with oculodentodigital dysplasia. Arch Ophthalmol. 2005;123:1422–6. doi:10.1001/archopht.123.10.1422.CrossRefPubMed

65.

Vitiello C, D’Adamo P, Gentile F, et al. A novel GJA1 mutation causes oculodentodigital dysplasia without syndactyly. Am J Med Genet A. 2005;133A:58–60. doi:10.1002/ajmg.a.30554.CrossRefPubMed

66.

Vreeburg M, de Zwart-Storm EA, Schouten MI, et al. Skin changes in oculo-dento-digital dysplasia are correlated with C-terminal truncations of connexin 43. Am J Med Genet A. 2007;143:360–3. doi:10.1002/ajmg.a.31558.CrossRefPubMed

67.

Wiest T, Herrmann O, Stogbauer F, et al. Clinical and genetic variability of oculodentodigital dysplasia. Clin Genet. 2006;70:71–2. doi:10.1111/j.1399-0004.2006.00631.x.CrossRefPubMed

68.

Flenniken AM, Osborne LR, Anderson N, et al. A Gja1 missense mutation in a mouse model of oculodentodigital dysplasia. Development. 2005;132:4375–86. doi:10.1242/dev.02011.CrossRefPubMed

69.

Hu Y, Chen IP, de Almeida S, et al. A novel autosomal recessive GJA1 missense mutation linked to craniometaphyseal dysplasia. PLoS ONE. 2013;8:e73576. doi:10.1371/journal.pone.0073576.CrossRefPubMedPubMedCentral

70.

Van Norstrand DW, Asimaki A, Rubinos C, et al. Connexin43 mutation causes heterogeneous gap junction loss and sudden infant death. Circulation. 2012;125:474–81. doi:10.1161/CIRCULATIONAHA.111.057224.CrossRefPubMed

71.

•• Shao Q, Lindstrom K, Shi R, et al. A germline variant in the PANX1 gene has reduced channel function and is associated with multisystem dysfunction. J Biol Chem. 2016;291:12432–43. doi:10.1074/jbc.M116.717934. The first report of a pannexin1 mutation associated with human disease. CrossRefPubMedPubMedCentral

72.

Plotkin LI. Connexin 43 hemichannels and intracellular signaling in bone cells. Front Physiol. 2014;5:131. doi:10.3389/fphys.2014.00131.CrossRefPubMedPubMedCentral

73.

Plotkin LI, Bellido T. Beyond gap junctions: Connexin43 and bone cell signaling. Bone. 2013;52:157–66. doi:10.1016/j.bone.2012.09.030.CrossRefPubMed

74.

Stains JP, Civitelli R. Connexins in the skeleton. Semin. Cell Dev. Biol. 2016;50:31–9. doi:10.1016/j.semcdb.2015.12.017.CrossRef

75.

Moorer MC, Stains JP. Connexin43 and the Intercellular Signaling Network Regulating Skeletal Remodeling. Curr. Osteoporos. Rep. 2017; doi:10.1007/s11914-017-0345-4.CrossRefPubMedPubMedCentral

76.

Araya R, Riquelme MA, Brandan E, et al. The formation of skeletal muscle myotubes requires functional membrane receptors activated by extracellular ATP. Brain Res Brain Res Rev. 2004;47:174–88. doi:10.1016/j.brainresrev.2004.06.003.CrossRefPubMed

77.

von Maltzahn J, Euwens C, Willecke K, et al. The novel mouse connexin39 gene is expressed in developing striated muscle fibers. J Cell Sci. 2004;117:5381–92. doi:10.1242/jcs.01413.CrossRef

78.

Araya R, Eckardt D, Riquelme MA, et al. Presence and importance of connexin43 during myogenesis. Cell Commun Adhes. 2003;10:451–6.CrossRefPubMed

79.

Araya R, Eckardt D, Maxeiner S, et al. Expression of connexins during differentiation and regeneration of skeletal muscle: functional relevance of connexin43. J Cell Sci. 2005;118:27–37. doi:10.1242/jcs.01553.CrossRefPubMed

80.

Langlois S, Xiang X, Young K, et al. Pannexin 1 and pannexin 3 channels regulate skeletal muscle myoblast proliferation and differentiation. J. Biol. Chem. 2014;289(44): 30717–31. doi:10.1074/jbc.M114.572131.CrossRef

81.

Riquelme MA, Cea LA, Vega JL, et al. Pannexin channels mediate the acquisition of myogenic commitment in C2C12 reserve cells promoted by P2 receptor activation. Front Cell Dev Biol. 2015;3:25. doi:10.3389/fcell.2015.00025.CrossRefPubMedPubMedCentral

82.

Buvinic S, Almarza G, Bustamante M, et al. ATP released by electrical stimuli elicits calcium transients and gene expression in skeletal muscle. J Biol Chem. 2009;284:34490–505. doi:10.1074/jbc.M109.057315.CrossRefPubMedPubMedCentral

83.

Riquelme MA, Cea LA, Vega JL, et al. The ATP required for potentiation of skeletal muscle contraction is released via pannexin hemichannels. Neuropharmacology. 2013;75:594–603. doi:10.1016/j.neuropharm.2013.03.022.CrossRefPubMed

84.

Jorquera G, Altamirano F, Contreras-Ferrat A, et al. Cav1.1 controls frequency-dependent events regulating adult skeletal muscle plasticity. J Cell Sci. 2013;126:1189–98. doi:10.1242/jcs.116855.CrossRefPubMed

85.

Cea LA, Puebla C, Cisterna BA, et al. Fast skeletal myofibers of mdx mouse, model of Duchenne muscular dystrophy, express connexin hemichannels that lead to apoptosis. Cell Mol Life Sci. 2016;73:2583–99. doi:10.1007/s00018-016-2132-2.CrossRefPubMed

86.

•• Cea LA, Cisterna BA, Puebla C, et al. De novo expression of connexin hemichannels in denervated fast skeletal muscles leads to atrophy. Proc Natl Acad Sci U S A. 2013;110:16229–34. doi:10.1073/pnas.1312331110. This paper describes a sequence of relevant events triggered in denervated skeletal muscles that lead to muscle atrophy and shows that de novo expressed connexin43 and connexin45 hemichannels are the cause of the myofibres ionic imbalance and negative protein balance of this muscles. CrossRefPubMedPubMedCentral

87.

Cisterna BA, Vargas AA, Puebla C, et al. Connexin hemichannels explain the ionic imbalance and lead to atrophy in denervated skeletal muscles. Biochim Biophys Acta. 2016;1862:2168–76. doi:10.1016/j.bbadis.2016.08.020.CrossRefPubMed

88.

Vargas AA, Cisterna BA, Saavedra-Leiva F, et al. On biophysical properties and sensitivity to gap junction blockers of connexin 39 hemichannels expressed in HeLa cells. Front Physiol. 2017;8:38. doi:10.3389/fphys.2017.00038.CrossRefPubMedPubMedCentral

89.

Schalper KA, Sánchez HA, Lee SC, et al. Connexin 43 hemichannels mediate the Ca²⁺ influx induced by extracellular alkalinization. Am J Physiol Cell Physiol. 2010;299:C1504–15. doi:10.1152/ajpcell.00015.2010.CrossRefPubMedPubMedCentral

90.

•• Schalper KA, Palacios-Prado N, Retamal MA, et al. Connexin hemichannel composition determines the FGF-1-induced membrane permeability and free [Ca2+]i responses. Mol Biol Cell. 2008;19:3501–13. doi:10.1091/mbc.E07-12-1240. This paper demonstrates that dexamethasone a synthetic glucocorticoids induces expression of connexin hemichannels in skeletal myofibers. This results in reduction in the resting membrane potential, activation of the protein degradation pathway, activation of the inflammasome, and atrophy. Therefore, it is proposed that glucocorticoids are anti-inflammarory in cells of the immune system but are inflammatory in skeletal muscles. CrossRefPubMedPubMedCentral

91.

Cea LA, Balboa E, Puebla C, et al. Dexamethasone-induced muscular atrophy is mediated by functional expression of connexin-based hemichannels. Biochim Biophys Acta. 2016;1862:1891–9. doi:10.1016/j.bbadis.2016.07.003.CrossRefPubMed

92.

Porter JD, Merriam AP, Leahy P, et al. Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Hum Mol Genet. 2003;12:1813–21.CrossRefPubMed

93.

Porter JD, Khanna S, Kaminski HJ, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002;11:263–72.CrossRefPubMed

94.

Spencer MJ, Montecino-Rodriguez E, Dorshkind K, et al. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol. 2001;98:235–43. doi:10.1006/clim.2000.4966.CrossRefPubMed

95.

Hodgetts S, Radley H, Davies M, et al. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul Disord. 2006;16:591–602. doi:10.1016/j.nmd.2006.06.011.CrossRefPubMed

96.

•• Cea LA, Bevilacqua JA, Arriagada C, et al. The absence of dysferlin induces the expression of functional connexin-based hemichannels in human myotubes. BMC Cell Biol. 2016;17 Suppl 1:15. doi:10.1186/s12860-016-0096-6. It demonstrates that myofibers of mdx mice, model of muscular dystrophy associated to mutation in dystrophin, express functional connexin hemichannels. In addition, it shows that these connexin hemichannels leads to increase in cytoplasmic Ca2+ signal, activation of NFkB, and apoptosis. CrossRefPubMed

97.

Whitehead NP, Streamer M, Lusambili LI, et al. Streptomycin reduces stretch-induced membrane permeability in muscles from mdx mice. Neuromuscul Disord. 2006;16:845–54. doi:10.1016/j.nmd.2006.07.024.CrossRefPubMed

98.

Figueroa VA, Retamal MA, Cea LA, et al. Extracellular gentamicin reduces the activity of connexin hemichannels and interferes with purinergic Ca²⁺ signaling in HeLa cells. Front Cell Neurosci. 2014;8:265. doi:10.3389/fncel.2014.00265.

99.

Balnave CD, Allen DG. Intracellular calcium and force in single mouse muscle fibres following repeated contractions with stretch. J Physiol. 1995;488(Pt 1):25–36. doi:10.1113/jphysiol.1995.sp020943.CrossRefPubMedPubMedCentral

100.

Yeung EW, Head SI. Allen, DG Gadolinium reduces short-term stretch-induced muscle damage in isolated mdx mouse muscle fibres. J Physiol. 2003;552:449–58. doi:10.1113/jphysiol.2003.047373.CrossRefPubMedPubMedCentral

101.

Bansal D, Miyake K. Vogel, SS et al Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423:168–72. doi:10.1038/nature01573.CrossRefPubMed

102.

Kerr JP, Ziman AP, Mueller AL, et al. Dysferlin stabilizes stress-induced Ca2+ signaling in the transverse tubule membrane. Proc Natl Acad Sci U S A. 2013;110:20831–6. doi:10.1073/pnas.1307960110.CrossRefPubMedPubMedCentral

103.

Turk R. Sterrenburg, E, van der Wees, CG et al Common pathological mechanisms in mouse models for muscular dystrophies. FASEB J. 2006;20:127–9. doi:10.1096/fj.05-4678fje.CrossRefPubMed

104.

Rawat R, Cohen TV. Ampong, B et al Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol. 2010;176:2891–900. doi:10.2353/ajpath.2010.090058.CrossRefPubMedPubMedCentral

105.

Cea LA, Riquelme MA, Cisterna BA, et al. Connexin- and pannexin-based channels in normal skeletal muscles and their possible role in muscle atrophy. J. Membr. Biol. 2012;245:423–36. doi:10.1007/s00232-012-9485-8.CrossRefPubMed

106.

Cisterna BA, Cardozo C. Sáez, JC Neuronal involvement in muscular atrophy. Front Cell Neurosci. 2014;8:405. doi:10.3389/fncel.2014.00405.CrossRefPubMedPubMedCentral

Title: Connexins and Pannexins in Bone and Skeletal Muscle
Authors: Lilian I. Plotkin
Hannah M. Davis
Bruno A. Cisterna
Juan C. Sáez
Publication date: 01-08-2017
Publisher: Springer US
Published in: Current Osteoporosis Reports / Issue 4/2017
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-017-0374-z

At a glance: The STEP trials

Springer Medicine

Connexins and Pannexins in Bone and Skeletal Muscle

Abstract

Purpose of review

Recent findings

Summary

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2017

Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors

In vivo Visualisation and Quantification of Bone Resorption and Bone Formation from Time-Lapse Imaging

microRNA Regulation of Skeletal Development

Response to “Clinical Evaluation of Bone Strength and Fracture Risk”

Recent Discoveries in Monogenic Disorders of Childhood Bone Fragility

Erratum to: Microcephalic Osteodysplastic Primordial Dwarfism, Type II: a Clinical Review